Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors

被引:106
作者
Coelmont, Lotte [1 ]
Kaptein, Suzanne [1 ]
Paeshuyse, Jan [1 ]
Vliegen, Inge [1 ]
Dumont, Jean-Maurice [2 ]
Vuagniaux, Gregoire [2 ]
Neyts, Johan [1 ]
机构
[1] KULeuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[2] Debiopharm, Lausanne, Switzerland
关键词
SERINE-PROTEASE INHIBITORS; IN-VITRO ACTIVITY; RIBAVIRIN ANTAGONIZES; CYCLOSPORINE-A; TYPE-1; REPLICATION; NUCLEOSIDE ANALOGS; POTENT INHIBITOR; RNA-SYNTHESIS; PHARMACOKINETICS; RESISTANCE;
D O I
10.1128/AAC.00939-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Debio 025 is a potent inhibitor of hepatitis C virus (HCV) replication (J. Paeshuyse et al., Hepatology 43: 761-770, 2006). In phase I clinical studies, monotherapy (a Debio 025 dose of 1,200 mg twice a day) resulted in a mean maximal decrease in the viral load of 3.6 log(10) units (R. Flisiak et al., Hepatology 47: 817-826, 2008), whereas a reduction of 4.6 log(10) units was obtained in phase II studies when Debio 025 was combined with interferon (R. Flisiak et al., J. Hepatol., 48: S62, 2008). We here report on the particular characteristics of the in vitro anti-HCV activities of Debio 025. The combination of Debio 025 with either ribavirin or specifically targeted antiviral therapy for HCV (STAT-C) inhibitors (NS3 protease or NS5B [nucleoside and nonnucleoside] polymerase inhibitors) resulted in additive antiviral activity in short-term antiviral assays. Debio 025 has the unique ability to clear hepatoma cells from their HCV replicon when it is used alone or in combination with interferon and STAT-C inhibitors. Debio 025, when it was used at concentrations that have been observed in human plasma (0.1 or 0.5 mu M), was able to delay or prevent the development of resistance to HCV protease inhibitors as well as to nucleoside and nonnucleoside polymerase inhibitors. Debio 025 forms an attractive drug candidate for the treatment of HCV infections in combination with standard interferon-based treatment and treatments that directly target the HCV polymerase and/or protease.
引用
收藏
页码:967 / 976
页数:10
相关论文
共 64 条
[1]   RIBAVIRIN ANTAGONIZES INHIBITORY EFFECTS OF PYRIMIDINE 2',3'-DIDEOXYNUCLEOSIDES BUT ENHANCES INHIBITORY EFFECTS OF PURINE 2',3'-DIDEOXYNUCLEOSIDES ON REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS INVITRO [J].
BABA, M ;
PAUWELS, R ;
BALZARINI, J ;
HERDEWIJN, P ;
DECLERCQ, E ;
DESMYTER, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1613-1617
[2]   Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication [J].
Blight, KJ ;
McKeating, JA ;
Rice, CM .
JOURNAL OF VIROLOGY, 2002, 76 (24) :13001-13014
[3]  
Carroll S. S., 2006, Infectious Disorders - Drug Targets, V6, P17, DOI 10.2174/187152606776056698
[4]   Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs [J].
Carroll, SS ;
Tomassini, JE ;
Bosserman, M ;
Getty, K ;
Stahlhut, MW ;
Eldrup, AB ;
Bhat, B ;
Hall, D ;
Simcoe, AL ;
LaFemina, R ;
Rutkowski, CA ;
Wolanski, B ;
Yang, ZC ;
Migliaccio, G ;
De Francesco, R ;
Kuo, LC ;
MacCoss, M ;
Olsen, DB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (14) :11979-11984
[5]   Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in owl monkey cells [J].
Chatterji, U ;
Bobardt, MD ;
Stanfield, R ;
Ptak, RG ;
Pallansch, LA ;
Ward, PA ;
Jones, MJ ;
Stoddart, CA ;
Scalfaro, P ;
Dumont, JM ;
Besseghir, K ;
Rosenwirth, B ;
Gallay, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (48) :40293-40300
[6]  
Chung Raymond T, 2008, Hepatology, V47, P306, DOI 10.1002/hep.22070
[7]   Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication [J].
Clark, JL ;
Mason, JC ;
Hollecker, L ;
Stuyver, LJ ;
Tharnish, PM ;
McBrayer, TR ;
Otto, MJ ;
Furman, PA ;
Schinazi, RF ;
Watanabe, KA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1712-1715
[8]   Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine [J].
Coelmont, Lotte ;
Paeshuyse, Jan ;
Windisch, Marc P. ;
De Clercq, Erik ;
Bartenschlager, Ralf ;
Neyts, Johan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3444-3446
[9]  
Craxi A, 2003, SEMIN LIVER DIS, V23, P35
[10]  
De Clercq E., 2009, V189, P53, DOI 10.1007/978-3-540-79086-0_3